Imatinib Promotes Osteoblast Differentiation by Inhibiting PDGFR Signaling and Inhibits Osteoclastogenesis by Both Direct and Stromal Cell-Dependent Mechanisms-Reference-Cited by-同舟云学术

Imatinib Promotes Osteoblast Differentiation by Inhibiting PDGFR Signaling and Inhibits Osteoclastogenesis by Both Direct and Stromal Cell-Dependent Mechanisms

Published:2007-07-30 Issue:11 Volume:22 Page:1679-1689
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J Bone Miner Res

Author:

O'Sullivan Susannah,Naot Dorit,Callon Karen,Porteous Fran,Horne Anne,Wattie Diana,Watson Maureen,Cornish Jill,Browett Peter,Grey Andrew

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Reference36 articles.

1. Imatinib mesylate-a new oral targeted therapy;Savage;N Engl J Med,2002

2. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib;Dewar;Blood,2005

3. FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance;Taylor;Oncogene,2006

4. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia;O'Brien;N Engl J Med,2003

5. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study;Verweij;Eur J Cancer,2003

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Tyrosine Kinase Inhibitors (TKIs) on Growth in Children and Adolescents with Chronic Myeloid Leukemia: A Systematic Review;Current Pharmaceutical Design;2024-09

2. Current perspectives on the multiple roles of osteoclasts: Mechanisms of osteoclast–osteoblast communication and potential clinical implications;eLife;2024-04-09

3. The Role of the Receptor Activator of Nuclear Factor Kappa-B Ligand/Osteoprotegerin Ratio in Vascular Diseases: A Therapeutic Approach;Angiology;2024-01-03

4. Systems genetics and bioinformatics analyses using ESR1-correlated genes identify potential candidates underlying female bone development;Genomics;2024-01

5. Treatment and follow‐up of children with chronic myeloid leukaemia in chronic phase (CML‐CP) in the tyrosine kinase inhibitor (TKI) era—Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort;British Journal of Haematology;2023-12-14